BCM
RLAY icon

Bayesian Capital Management’s Relay Therapeutics RLAY Stock Holding History

Bayesian Capital Management’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-43,900
Closed -$286K – 986
2024
Q2 		$286K Buy
43,900
+5,300
+14% +$36.2K 0.03% 516
2024
Q1 		$320K Buy
+38,600
New +$377K 0.03% 541
2023
Q2 		– Sell
-30,500
Closed -$502K – 1021
2023
Q1 		$502K Buy
+30,500
New +$547K 0.06% 390

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Bayesian Capital Management's RLAY Position: Q3 2024 in Review

Bayesian Capital Management sold out of Relay Therapeutics (RLAY) in Q3 2024, closing a stake of 43,900 shares — an estimated $286K sold.

Bayesian Capital Management first reported a position in RLAY in Q1 2023 and held it in 3 quarters. The position peaked at $502K in Q1 2023. 195 funds tracked by Wall St. Rank hold RLAY as of Q3 2024.

  • Bayesian Capital Management reported no remaining Relay Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Bayesian Capital Management sold 43,900 Relay Therapeutics shares in Q3 2024, an estimated $286K.
  • Bayesian Capital Management first reported a position in Relay Therapeutics in Q1 2023 and held it in 3 quarters.
  • Bayesian Capital Management's Relay Therapeutics position peaked at $502K in Q1 2023.
  • 195 funds tracked by Wall St. Rank held Relay Therapeutics as of Q3 2024.

Based on Bayesian Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.